BLBoya Liao

Boya Liao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Boya Liao has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • BCKDK, A Novel Hypoxia-Responsive Kinase That Exacerbates Cerebral Ischemia Injury

    by Boya Liao, Fang Zhang, Chang Han, Xinyao Yi, Ziyi Zhang, Leigang Jin, Fei Meng, Stanley Sau-Ching Wong, Ruby L.C. Hoo, Leiluo Geng, et al.

    BACKGROUND: Alterations in circulating amino acid profiles have been observed in ischemic stroke patients; however, whether cerebral ischemia disrupts amino acid metabolism within brain tissue and whether this disruption contributes to cellular stress and cerebral injury remain unknown. This hypothesis-testing study investigates disrupted BCAA (branched-chain amino acid) catabolism as a key mechanism of ischemic brain damage and evaluates BCKDK (branched-chain α-keto acid dehydrogenase kinase) as a novel therapeutic target. METHODS: Mouse primary cortical neurons subjected to oxygen-glucose deprivation and brain tissue from a mouse acute ischemic stroke model were used as experimental systems. Untargeted metabolomics and metabolic flux analysis were used to characterize BCAA metabolism in both models. In vivo pharmacological inhibition or in vitro knockdown of BCKDK was performed using BT2 (3,6-dichlorobenzo[b]thiophene-2-carboxylic acid) treatment or RNA interference. Primary outcome variables included infarct volume, BCKDH (branched-chain α-keto acid dehydrogenase) enzyme activity, neuronal viability, and markers of energy metabolism and glutamate excitotoxicity. Between-group differences were evaluated using 1-way ANOVA; data are presented as mean ± SD with 95% CIs and corresponding P values. RESULTS: Metabolomics analysis of oxygen-glucose deprivation-exposed primary neurons revealed impaired BCAA catabolism and significant BCAA accumulation compared with normoxic controls. In ischemic mouse brain tissue, BCKDH activity was significantly suppressed, and BCKDK expression was markedly upregulated relative to sham-operated animals. Both pharmacological and genetic suppression of BCKDK substantially reduced cerebral ischemic injury, as evidenced by decreased infarct volume and improved neuronal survival (95% CI and P values per comparison). Mechanistically, ischemia-induced BCKDK expression via HIF-1α (hypoxia-inducible factor 1α)-mediated transcriptional activation, which inhibited BCAA conversion to tricarboxylic acid cycle substrates, thereby potentiating energy deficiency and glutamate excitotoxicity. CONCLUSIONS: These data identify BCKDK as a novel hypoxia-responsive factor whose upregulation drives disrupted BCAA catabolism as a key mechanism of ischemic neuronal injury. BCKDK represents a promising therapeutic target for cerebral ischemia, directly supported by both in vitro and in vivo experimental evidence presented here.

  • Open Access

    Induced Pluripotent Stem Cell-Based Platforms for Cardiac-Related Pain Research: Molecular Mechanisms, Experimental Models, and Therapeutic Applications

    by Boya Liao, Aaron Kin-Ho Lee, Zheng Gu, Fei Meng, Jiangwei Wu, Jinghan Yang, Stanley Sau-Ching Wong

    Cardiac-related pain, including angina pectoris and pain accompanying myocardial infarction, remains clinically important, and existing treatments are inadequate for some patients. Animal and primary-tissue studies provide important mechanistic evidence, but species differences and limited access to patient-matched human neuro-cardiac tissue constrain translation. This review synthesizes the following separate advances relevant to future human iPSC-based cardiac-pain modeling: molecular mechanisms that may be reconstructed in vitro; platforms ranging from two-dimensional cultures to proposed sensory-innervated three-dimensional and microfluidic systems; and potential applications in target validation, patient-specific modeling, and analgesic screening. We distinguish direct human iPSC evidence from findings obtained in animal, primary-cell, cardiac-only, autonomic-neuron, or non-cardiac pain models. We also discuss maturation, standardization, and regulatory challenges. iPSC technologies may complement existing models and support mechanism-focused, patient-stratified research, but direct validation in human sensory–neuron–cardiac systems remains limited.

  • Open Access

    A short-term high-fat diet induced acute postoperative pain priming through impairing SerpinB6 protein-mediated M2 macrophage polarization

    by Jingjing Liu, Fei Meng, Boya Liao, Chris Kwan Yin Gu, Aijia Jessica Liu, Yingfu Jiao, Stanley Sau Ching Wong

  • Open Access

    Harnessing Induced Pluripotent Stem Cells for Cardiac-Related Pain: Advances, Models, and Therapeutic Prospects

    by Boya Liao, Kin-Ho Aaron Lee, Fei Meng, Jiangwei Wu, Jinghan Yang, Sau-Ching Stanley Wong

    Cardiac pain is difficult to diagnose and treat in part because existing models fail to capture human neuro-cardiac signaling. This review examines how iPSC-derived cardiomyocytes and sensory neurons in co-culture and organoid systems model ischemic and neuro-immune mechanisms, and how such platforms enable regenerative and neuromodulatory translation. We identify key barriers (maturation, heterogeneity, scalability, safety) and propose priorities to bridge discovery and clinical application.

  • β-Klotho promotes glycolysis and glucose-stimulated insulin secretion via GP130

    by Leiluo Geng, Boya Liao, Leigang Jin, Jiasui Yu, Xiaoyu Zhao, Yuntao Zhao, Ling Zhong, Baile Wang, Jiufeng Li, Jie Liu, et al.

    Impaired glucose-stimulated insulin secretion (GSIS) is a hallmark of type-2 diabetes. However, cellular signaling machineries that control GSIS remain incompletely understood. Here, we report that β-klotho (KLB), a single-pass transmembrane protein known as a co-receptor for fibroblast growth factor 21 (FGF21), fine tunes GSIS via modulation of glycolysis in pancreatic β-cells independent of the actions of FGF21. β-cell-specific deletion of Klb but not Fgf21 deletion causes defective GSIS and glucose intolerance in mice and defective GSIS in islets of type-2 diabetic mice is mitigated by adenovirus-mediated restoration of KLB. Mechanistically, KLB interacts with and stabilizes the cytokine receptor subunit GP130 by blockage of ubiquitin-dependent lysosomal degradation, thereby facilitating interleukin-6-evoked STAT3–HIF1α signaling, which in turn transactivates a cluster of glycolytic genes for adenosine triphosphate production and GSIS. The defective glycolysis and GSIS in Klb-deficient islets are rescued by adenovirus-mediated replenishment of STAT3 or HIF1α. Thus, KLB functions as a key cell-surface regulator of GSIS by coupling the GP130 receptor signaling to glucose catabolism in β-cells and represents a promising therapeutic target for diabetes.


  • Open Access

    Fatty acid binding protein 4 promotes autoimmune diabetes by recruitment and activation of pancreatic islet macrophages

    by Yang Xiao, Lingling Shu, Xiaoping Wu, Yang Liu, Lai Yee Cheong, Boya Liao, Xiaoyu Xiao, Ruby L.C. Hoo, Zhiguang Zhou, Aimin Xu

    Both innate and adaptive immune cells are critical players in autoimmune destruction of insulin-producing β cells in type 1 diabetes. However, the early pathogenic events triggering the recruitment and activation of innate immune cells in islets remain obscure. Here we show that circulating fatty acid binding protein 4 (FABP4) level was significantly elevated in patients with type 1 diabetes and their first-degree relatives and positively correlated with the titers of several islet autoantibodies. In nonobese diabetic (NOD) mice, increased FABP4 expression in islet macrophages started from the neonatal period, well before the occurrence of overt diabetes. Furthermore, the spontaneous development of autoimmune diabetes in NOD mice was markedly reduced by pharmacological inhibition or genetic ablation of FABP4 or adoptive transfer of FABP4-deficient bone marrow cells. Mechanistically, FABP4 activated innate immune responses in islets by enhancing the infiltration and polarization of macrophages to proinflammatory M1 subtype, thus creating an inflammatory milieu required for activation of diabetogenic CD8 + T cells and shift of CD4 + helper T cells toward Th1 subtypes. These findings demonstrate FABP4 as a possible early mediator for β cell autoimmunity by facilitating crosstalk between innate and adaptive immune cells, suggesting that pharmacological inhibition of FABP4 may represent a promising therapeutic strategy for autoimmune diabetes.